Update multiple endocrine neoplasia type 2

Familial Cancer

Volumn 9, Issue 3, 2010, Pages 449-457

  Raue, Friedhelm ^a,b   Frank Raue, Karin ^b  

^a Endocrine Practice   (Germany)

^b Endokrinologische Gemeinschaftspraxis   (Germany)

Author keywords

Ganglioneuromarosis; Multiple endocrine neoplasia type 2; Pheochromocytoma; Primary hyperparathyroidism; RET proto oncogene; Tyrosine kinase inhibitors

Indexed keywords

CALCITONIN;

ARTICLE; CANCER CYTODIAGNOSIS; CHROMOSOME 10; FAMILIAL CANCER; FOLLOW UP; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HEALTH ECONOMICS; HETEROZYGOTE; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2; PATIENT COUNSELING; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROGNOSIS; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

GENETIC ASSOCIATION STUDIES; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; RISK FACTORS;

EID: 78650184526     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-010-9320-2     Document Type: Article

References (41)

1. Mulligan LM, Kwok JBJ, Healey CS et al (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2a (MEN 2A). Nature 363:458-469
2. Donis-Keller H, Dou S, Chi D et al (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genetics 2:851-856
3. Raue F, Frank-Raue K, Grauer A (1994) Multiple endocrine neoplasia type 2, clinical features and screening. Endocrin Metab Clin North Am 23:137-156
4. Brandi ML, Gagel R, Angeli A et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658-5671
5. Vasen HF, van der Feltz M, Raue F et al (1992) The natural course of multiple endocrine neoplasia type 2 b. Arch Intern Med 152:1250-1252
6. Berndt I, Reuter M, Saller B et al (1998) A new hotspot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83:770-774
7. Kloos RT, Eng C, Evans DB et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565-612
8. Brauckhoff M, Machens A, Hess S et al (2008) Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis. Surgery 144:1044-1051
9. Eng C, Mulligan LM, Smith DP et al (1995) Low frequency of germline mutations in the RET protooncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 43:123-127
10. Machens A, Niccoli-Sire P, Hoegel J et al (2003) Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517-1525
11. LiVolsi VA (1997) C cell hyperplasia/neoplasia. J Clin Endocrinol Metab 82:39-41
12. Grauer A, Raue F, Ziegler R (1998) Clinical usefullness of a new chemoluminescent two-site immunoassy for human calcitonin. Exp Clin Endorcinol Diabetes 106:353-359
13. Cohen R, Campos JM, Salaün C et al (2000) Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. J Clin Endocrinol Metab 85:905-918
14. Mathew CG, Chin KS, Easton DF et al (1987) A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328:527-528
15. Romei C, Elisei R, Pinchera A et al (1996) Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 81:1619-1622
16. Elisei R, Cosci B, Romei C et al (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682-687
17. Mulligan LM, Marsh DJ, Robinson BG et al (1995) Genotypephenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Int Med 238:343-346
18. Eng C, Clayton D, Schuffenecker I et al (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis. JAMA 276:1575-1579
19. Frank-Raue K, Höppner W, Frilling A et al (1996) Mutations of the RET proto-oncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin Endocrinol Metab 81:1780-1783
20. Machens A, Brauckhoff M, Holzhausen HJ et al (2005) Codonspecific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 90:3999-4003
21. Quayle FJ, Fialkowski EA, Benveniste R et al (2007) Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 142:800-805
22. Schuffenecker I, Virally-Monod M, Brohet R et al (1998) Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. J Clin Endocrinol Metab 83:487-491
23. Kouvaraki MA, Shapiro SE, Perrier ND et al (2005) RET protooncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15:531-544
24. Frank-Raue K, Rondot S, Schulze e et al (2007) Change in the spectrum of RET mutations diagnosed between 1994 and 2006. Clin Lab 53:273-282
25. Moers AM, Lansvater RM, Schaap C et al (1996) Familial medullary thyroid carcinoma: not a distinct entity? Genotypephenotype correlation in a large family. Am J Med 101:635-641
26. Bolino A, Schuffenecker I, Luo y et al (1995) RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10:2415-2419
27. Smith DP, Houghton C, Ponder BA (1995) Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15:1213-1217
28. Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803
29. Neumann HP, Bausch B, McWhinney SR et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459-1466
30. Frank-Raue K, Machens A, Scheuba C et al (2008) Difference in the development of medullary thyroid carcinoma among carriers of RET mutations in codon 790 and 791. Clin Endocrinol 69:259-263
31. Frank-Raue K, Buhr H, Dralle H et al (2006) Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 155:229-236
32. Moley JF, Fialkowski EA (2007) Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 31:946-956
33. Giraudet AL, Al Ghulzan A, Auperin A et al (2008) Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158:239-246
34. Ball DW (2007) Medullary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin N Am 36:823-837
35. Sherman SI (2009) Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94:1493-1499
36. Raue F (1998) German medullary thyroid carcinoma/multiple endocrine neoplasia registry. Langenbeck's Arch Surg 383:334-336
37. Kebebew E, Ituarte PHG, Siperstein AE et al (2000) Medullary thyroid carcinoma, clinical characteristics, treatment, prognostic factors and a comparison of staging systems. Cancer 88:1139-1148
38. Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathological predictors of survival in 1252 cases. Cancer 107:2134-2142
39. de Groot JW, Plukker JTM, Wolffenbuttel BHR (2006) Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol 65:729-736
40. Bergholm U, Bergstrom R, Ekbom A (1997) Long-term followup of patients with medullary carcinoma of the thyroid. Cancer 79:132-138
41. Skinner MA, Moley JA, Dilley WG et al (2005) Prophylactic thyroidectomy in multiple endocrine neoplasia type 2. N Engl J Med 353:1105-1113